Research Focus

Clinical Pharmacology

Area of Research

HIV pharmacology with a focus on drug interactions and pharmacokinetics in specialized populations

Approved Research Projects

Use of PBPK modelling to simulate bictegravir pharmacokinetics and DDIs in elderly patients living with HIV
Use of PBPK modelling to simulate dosing requirements of long-acting intramuscular antiretroviral drugs in special populations and to manage DDIs
Real-life clinical management of DDIs between antiretrovirals and various comedications in patients of the SHCS
Impact of non-HIV drugs on neurocognitive performance in the NAMACO patients
Anticholinergic drug use in elderly patients of the SHCS
Recognition of clinically relevant DDIs in the KIULARCO Cohort
Prevalence of potentially inappropriate medication use in elderly patients of the SHCS
Development of permeability rate limited PBPK models to simulate DDIs at the hepatic level
Use of PBPK modelling to simulate DDIs between antiretrovirals and commonly prescribed comedications in the aging HIV population

Collaborations

National Collaborations

Prof. L. Decosterd and Dr. F. Livio. Division of clinical pharmacology, University Hospital Lausanne
Prof. M. Cavassini. Division of Infectious Diseases, University Hospital Lausanne
Prof. M. Penny; PD Dr. M. Weisser and Dr. A. Kummerle. Swiss Tropical Institute, Basel
Representatives of the HIV centers participating to the SHCS
Prof. H. Bucher. Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel
Prof. G. Moffa. Department of Mathematics, University of Basel

International Collaborations

Prof. D. Back; Prof. S. Khoo and Dr. M. Siccardi. Department of Molecular and Clinical Pharmacology, University of Liverpool, UK
Prof. B. Jakeman. Department of Pharmaceutical Practice and Administrative Sciences, University of New Mexico, Albuquerque, USA

Ongoing Research Projects

Simulation of the pharmacokinetics in elderly patients living with HIV and management of DDIs for the novel antiretroviral drug bictegravir
Gender differences in the pharmacokinetics of antiretroviral drugs
Prevalence of DDIs in the patients of the SHCS in the era of integrase inhibitors. Unboosted integrase inhibitors are characterized by a lower potential for DDIs. This project aims at evaluating whether the use of unboosted integrase inhibitors has led to a significant reduction in the prevalence of DDIs in patients of the SHCS. Results of this analysis will be compared to a previous analysis of the SHCS conducted 10 years ago (Marzolini C et al. Antivir Ther 2010)

[FG] Marzolini Catia

Members